Sarah Holstein, MD, PhD, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.
Sarah Holstein, MD, PhD, associate professor at the University of Nebraska Medical Center, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.
Holstein does not use quadruplet regimens outside of clinical trials because the treatment paradigm is not quite there, she says. However, she tries to use triplet combinations in the majority of her patients.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More